Compare UHS & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHS | KYMR |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.6B |
| IPO Year | 1994 | 2020 |
| Metric | UHS | KYMR |
|---|---|---|
| Price | $179.08 | $114.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 26 |
| Target Price | ★ $216.36 | $107.72 |
| AVG Volume (30 Days) | ★ 669.1K | 608.0K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | ★ 37.34 | N/A |
| EPS | ★ 11.63 | N/A |
| Revenue | ★ $17,364,829,000.00 | $39,211,000.00 |
| Revenue This Year | $7.67 | $10.61 |
| Revenue Next Year | $4.99 | $8.17 |
| P/E Ratio | $15.22 | ★ N/A |
| Revenue Growth | ★ 9.71 | N/A |
| 52 Week Low | $140.08 | $54.09 |
| 52 Week High | $246.33 | $130.05 |
| Indicator | UHS | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 44.32 |
| Support Level | $163.44 | $110.64 |
| Resistance Level | $186.91 | $120.37 |
| Average True Range (ATR) | 6.06 | 4.97 |
| MACD | 0.03 | -0.51 |
| Stochastic Oscillator | 61.91 | 22.86 |
Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.